IRIS
CASADEI GARDINI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 766
NA - Nord America 739
AS - Asia 303
SA - Sud America 10
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 1
Totale 1.825
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 733
SE - Svezia 464
SG - Singapore 227
RU - Federazione Russa 170
IT - Italia 59
CN - Cina 51
FI - Finlandia 23
DE - Germania 21
NL - Olanda 9
GB - Regno Unito 8
IE - Irlanda 7
IN - India 7
BR - Brasile 6
IR - Iran 6
JP - Giappone 6
AR - Argentina 4
CA - Canada 4
EU - Europa 4
FR - Francia 3
PH - Filippine 3
A1 - Anonimo 2
MX - Messico 2
AU - Australia 1
BD - Bangladesh 1
CZ - Repubblica Ceca 1
ES - Italia 1
HK - Hong Kong 1
IL - Israele 1
Totale 1.825
Salva come PNG Salva come JPEG
Città #
New York 202
Lawrence 149
Princeton 149
Singapore 107
Moscow 51
Ashburn 46
Boardman 44
Shanghai 41
Helsinki 22
Milan 10
Hanover 8
Rome 8
Seattle 8
Washington 8
Dublin 7
Dronten 4
London 4
Los Angeles 4
Martinez 4
Durham 3
Amsterdam 2
Berlin 2
Brighton 2
Foggia 2
Fukushima 2
Kish 2
Lucca 2
Ludhiana 2
Lyon 2
Manila 2
Mexico City 2
Pune 2
Rimini 2
Roseto degli Abruzzi 2
Santa Clara 2
Tokyo 2
Visakhapatnam 2
Aioicho 1
Andover 1
Ann Arbor 1
Bari 1
Beijing 1
Birmingham 1
Bologna 1
Borås 1
Boston 1
Brescia 1
Brisbane 1
Central 1
Clifton 1
Delhi 1
Goala Bazar 1
Hamm 1
João Pessoa 1
Kashan 1
Lappeenranta 1
Leawood 1
Macael 1
Mountain View 1
Naaldwijk 1
New Orleans 1
Noicattaro 1
Nuremberg 1
Oldham 1
Pisa 1
Pontirolo Nuovo 1
Redwood City 1
Rockville 1
Sacramento 1
San Francisco 1
Tarlac City 1
Venezia 1
Vezzano sul Crostolo 1
Winnipeg 1
Zola Predosa 1
Totale 951
Salva come PNG Salva come JPEG
Nome #
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 28
Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities 24
Platelets and hepatocellular cancer: Bridging the bench to the clinics 22
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 20
ROS1 rearrangements are uncommon in biliary tract cancers 20
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study 20
EUS-guided GastroEnterostomy for management of malignant Gastric Outlet Obstruction: a prospective cohort study with matched comparison with Enteral Stenting 19
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 19
BRAF-mutated colorectal cancer: Clinical and molecular insights 19
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 18
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 18
Mtor pathway expression as potential predictive biomarker in patients with advanced neuroendocrine tumors treated with everolimus 18
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 18
Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: Ready for Prime Time? 18
Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours 17
BRCA in gastrointestinal cancers: Current treatments and future perspectives 17
The role of anti-angiogenics in pre-treated metastatic BRAF-mutant colorectal cancer: A pooled analysis 17
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 17
Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery 17
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 17
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 17
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 16
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 16
1H-NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages 16
Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: A case report and results from a cytoflourimetric assay of platelet fibrinogen receptor 16
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 16
Atezolizumab and bevacizumab in advanced HCC: ready for prime time? 16
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease 15
Retrospective Analysis on the Management of Metastatic Gastric Cancer Patients. A Mono-institutional Experience. What happens in Clinical Practice? 15
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 15
Sorafenib for the treatment of unresectable hepatocellular carcinoma: Preliminary toxicity and activity data in dogs 15
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study (Targeted Oncology, (2020), 15, 1, (115-126), 10.1007/s11523-020-00698-x) 15
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 14
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 14
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 14
Preoperative Chemotherapy and Resection Margin Status in Colorectal Liver Metastasis Patients: A Propensity Score-Matched Analysis 14
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 14
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 14
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 14
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 14
Cholangiocarcinoma: new perspectives for new horizons 14
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 14
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 14
Hemangioblastoma of the gastrointestinal tract: A first case 13
Radiofrequency Ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival 13
Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report 13
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 13
Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy 13
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 13
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: Results from a retrospective analysis of the HCC-AVR group 13
NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus 13
Sarcopenia in gastric cancer: when the loss costs too much 13
EGFR, HER-2 and KRAS in canine gastric epithelial tumors: A potential human model? 13
Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study 13
Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials 13
Developments in predictive biomarkers for hepatocellular carcinoma therapy 13
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus 13
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 13
Predictive and prognostic factors in HCC patients treated with sorafenib 13
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 13
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 13
HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples 12
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 12
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 12
Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer 12
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: Indicators of suspected adverse reactions 12
Incorporating alpha-fetoprotein within dimensional criteria for hepatocellular carcinoma transplantation 12
Complete Response in Patient with Metastatic Breast Cancer Treated with Metronomic Chemotherapy 12
Oxidative Molecular Mechanisms Underlying Liver Diseases: From Systems Biology to the Personalized Medicine 12
Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals 12
Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial 12
Immunotherapy for colorectal cancer: where are we heading? 12
NEMESI: A retrospective observational longitudinal study to investigate italian early breast cancer (EBC) patient characteristics and treatment 12
Improved stool DNA integrity method for early colorectal cancer diagnosis 12
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 12
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 12
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib 12
The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT 12
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 12
The Italian Rare Pancreatic Exocrine Cancer Initiative 12
Monofocal hepatocellular carcinoma: How much does size matter? 12
Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life 12
KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC) 12
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 11
Retrospective Evaluation and Significance of Neutrophil-to-Lymphocyte Ratio Prior to and 1 month Following Microwave Ablation of Hepatocellular Carcinoma 11
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma 11
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 11
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: Case report 11
IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab 11
Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study 11
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 11
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 11
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 11
Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study 11
Metabolic disorders across hepatocellular carcinoma in Italy 11
Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison 11
Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis 11
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib 11
Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis (Targeted Oncology, (2021), 16, 3, (401-410), 10.1007/s11523-021-00797-3) 11
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? 10
Totale 1.409
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.198
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.198
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021130 0 0 0 77 0 51 1 1 0 0 0 0
2021/2022100 0 0 0 40 2 5 15 22 6 2 0 8
2022/2023842 325 171 70 12 2 123 25 46 49 5 6 8
2023/2024661 35 18 58 54 33 226 73 44 0 11 24 85
2024/2025331 331 0 0 0 0 0 0 0 0 0 0 0
Totale 2.064